Recursion Pharmaceuticals (NASDAQ:RXRX) Sets New 1-Year Low – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price hit a new 52-week low on Wednesday . The company traded as low as $3.31 and last traded at $3.46, with a volume of 17108446 shares. The stock had previously closed at $3.49.

Wall Street Analyst Weigh In

Several research analysts recently commented on RXRX shares. Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. UBS Group set a $11.00 price objective on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Finally, JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the company from $10.00 to $11.00 in a report on Wednesday, December 17th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Price Performance

The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1.80 billion, a P/E ratio of -1.92 and a beta of 0.95. The stock has a fifty day moving average of $4.31 and a 200-day moving average of $4.80.

Insider Activity at Recursion Pharmaceuticals

In other news, insider Najat Khan sold 124,403 shares of the company’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $4.41, for a total transaction of $548,617.23. Following the transaction, the insider owned 611,135 shares of the company’s stock, valued at $2,695,105.35. This represents a 16.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Ben R. Taylor sold 21,383 shares of the firm’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $4.18, for a total transaction of $89,380.94. Following the completion of the transaction, the chief financial officer directly owned 761,550 shares in the company, valued at $3,183,279. This trade represents a 2.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 805,786 shares of company stock valued at $3,482,598 over the last quarter. Corporate insiders own 8.43% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Large investors have recently bought and sold shares of the business. TD Waterhouse Canada Inc. boosted its stake in Recursion Pharmaceuticals by 64.1% in the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after acquiring an additional 2,200 shares during the last quarter. International Assets Investment Management LLC bought a new position in shares of Recursion Pharmaceuticals in the 4th quarter worth $31,000. Sequoia Financial Advisors LLC bought a new position in shares of Recursion Pharmaceuticals in the 4th quarter worth $41,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Recursion Pharmaceuticals by 97.2% during the second quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock worth $46,000 after purchasing an additional 4,446 shares during the period. Finally, Allworth Financial LP increased its holdings in Recursion Pharmaceuticals by 85.6% in the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after purchasing an additional 4,403 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.